Treace Medical Concepts, Inc. (TMCI)

Treace Medical Concepts' stock (TMCI) has declined significantly in the past six months. In Q1 2026, the company reported a loss of $0.28 per share, beating estimates, with revenue of $47.2 million, exceeding expectations but declining 10% year-over-year due to a shift towards lower-priced minimally invasive products and reduced sales of bunion procedure kits. Management reaffirmed its full-year 2026 revenue guidance of $202 million to $212 million, expecting revenue declines to continue until the fourth quarter, with growth returning due to accelerating case volumes, the anniversary of the product mix shift, and contributions from planned 2026 product launches. New product innovations launched in 2025 and planned launches in 2026 are central to its growth strategy.

Demand for Treace Medical Concepts' products and services exhibits seasonality, with the fourth quarter typically being the strongest. The company expects revenue growth to return in the fourth quarter of 2026, supported by accelerating case volumes, the anniversary of the product mix shift, and contributions from planned 2026 product launches. The first quarter of 2026 saw a revenue decline, partly attributed to a shift towards lower-priced minimally invasive products, and the company anticipates revenue declines to continue until the fourth quarter.

Treace Medical Concepts, Inc. (TMCI) is a medical technology company focused on foot and ankle surgical devices and biologics, particularly for bunion and midfoot deformities. Its major products include the Lapiplasty® 3D Bunion Correction® System, Adductoplasty® Midfoot Correction System, Hammertoe PEEK Fixation System, SpeedMTP™ Rapid Compression Implant, Nanoplasty™ 3D Minimally Invasive Bunion Correction System, Percuplasty™ Percutaneous 3D Bunion Correction System, SpeedPlate™ Rapid Compression Implants, and the upcoming SuperBite™ Compression Screw System and SpeedXM.

Treace Medical Concepts primarily operates in the United States, serving orthopedic surgeons, podiatrists, hospitals, and ambulatory surgery centers. The company is expanding its adoption among North American orthopedic surgical centers and has initiated selective international distributor pilot programs in European markets in late 2024, with plans for regulatory and commercial expansion into Asia-Pacific markets in 2025.

Treace Medical Concepts aims to advance the standard of care for surgical management of bunion and related midfoot deformities. The company emphasizes surgeon education and support to ensure effective adoption of its technologies. Its Lapiplasty system is noted for its 3D correction approach, which has disrupted the bunion market by reducing recurrence rates compared to traditional 2D methods. Treace is committed to operating with high ethical standards and adheres to the AdvaMed Code.

Institutional investors are the dominant shareholders in Treace Medical Concepts, holding over 60% of the company's stock. Major institutional owners include Armistice Capital LLC, BlackRock, Inc., The Vanguard Group, CIBC Bancorp USA Inc., Gagnon Securities Llc, Bank Of America Corp /de/, Millennium Management Llc, CIBC Private Wealth Group, LLC, First Eagle Investment Management, LLC, William Blair Investment Management, Llc and StepStone Group LP. The largest individual shareholder is John T. Treace, the CEO and Founder.